Immunomedics (IMMU) is a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. This stock is trading up 4.4% at $3.51 in recent trading.
Today's Range: $3.42-$3.6552-Week Range: $2.85-$4.27 Volume: 403,000 Three-Month Average Volume: 278,730 Shares of IMMU are soaring today after the company said that their scientists have published an article in the current issue of the journal, PLoS One, describing their collaboration in the design and testing of a new class of drugs that significantly destroyed the AIDS virus, HIV, and may potentially eradicate the virus completely. >>Hot Biotech Stocks Traded by Hedge Funds From a technical perspective, IMMU is soaring here back above its 200-day at $3.45 and its 50-day moving averageat $3.47 with heavy volume. This stock has also briefly flirted with a near-term breakout today, since shares have challenged some overhead resistance at $3.60. At last check, IMMU has hit an intraday high of $3.65 and volume is well above its three-month average action of 278,730 shares. Traders should now look for long-biased trades as long as IMMU is trending above $3.60 to $3.76 with strong upside volume flows. I would consider any upside volume day that registers near or above 278,730 shares as bullish. If we get that action for IMMU, then I expect this stock to re-test and possibly take out $4 to $4.45 in the near future.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV